Blood Pressure - PCa survival. The PROCA-life study.

[pjoshea13]

New study from Norway below [1].

"... we examined the association between prediagnostic BP and prostate cancer risk among 12,271 men participating in the Prostate Cancer throughout life (PROCA-life) study. Systolic and diastolic BP were measured. A total of 811 men developed prostate cancer, and followed for additional 7.1 years, and we studied the association between prediagnostic BP and overall mortality among patients with prostate cancer."

"Men (>45 years) with a systolic BP >150 mmHg had a 35% increased risk of prostate cancer compared with men with a normal systolic BP (<130 mmHg) (HR 1.35 ...). Among patients with prostate cancer, men with systolic BP >150 mmHg had a 49% increased overall mortality compared with men with a normal systolic BP (HR 1.49 ...). Among patients with prostate cancer treated with curative intent, those with a high diastolic BP (>90 mmHg) had a threefold increase in overall mortality risk (HR 3.01 ...) compared with patients with a normal diastolic BP (<80 mmHg).".

***

Time to consider an ARB?:

healthunlocked.com/advanced...

-Patrick

[1] pubmed.ncbi.nlm.nih.gov/349...

Cancer Med

. 2021 Dec 22. doi: 10.1002/cam4.4523. Online ahead of print.

Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study

Einar Stikbakke 1 2 , Henrik Schirmer 3 4 , Tore Knutsen 1 5 , Martin Støyten 1 2 , Tom Wilsgaard 6 , Edward L Giovannucci 7 8 , Anne McTiernan 9 10 , Anne E Eggen 6 , Hege S Haugnes 1 2 , Elin Richardsen 11 12 , Inger Thune 1 13 14

Affiliations collapse

Affiliations

1 Department of Clinical Medicine, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway.

2 Department of Oncology, University Hospital of North Norway, Tromsø, Norway.

3 Department of Cardiology, Akershus University Hospital, Lørenskog, Norway.

4 Institute of Clinical Medicine Campus Ahus, University of Oslo, Oslo, Norway.

5 Department of Urology, University Hospital of North Norway, Tromsø, Norway.

6 Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway.

7 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

8 Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

9 Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

10 Department of Epidemiology, School of Public Health, and Department of Medicine, School of Medicine, University of Washington, Seattle, Washington, USA.

11 Department of Medical Biology, Faculty of Health Sciences, UiT, The Arctic University of Norway, Tromsø, Norway.

12 Department of Pathology, University Hospital of North Norway, Tromsø, Norway.

13 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

14 Department of Oncology, The Cancer Centre, Ullevaal, Oslo University Hospital, Oslo, Norway.

PMID: 34939344 DOI: 10.1002/cam4.4523

Abstract

Background: Inflammation has been linked to prostate cancer and hypertension, but it remains equivocal whether elevated blood pressure (BP) influence prostate cancer risk and survival.

Method: Using Cox regression models, we examined the association between prediagnostic BP and prostate cancer risk among 12,271 men participating in the Prostate Cancer throughout life (PROCA-life) study. Systolic and diastolic BP were measured. A total of 811 men developed prostate cancer, and followed for additional 7.1 years, and we studied the association between prediagnostic BP and overall mortality among patients with prostate cancer.

Results: Men (>45 years) with a systolic BP >150 mmHg had a 35% increased risk of prostate cancer compared with men with a normal systolic BP (<130 mmHg) (HR 1.35, 95% CI 1.08-1.69). Among patients with prostate cancer, men with systolic BP >150 mmHg had a 49% increased overall mortality compared with men with a normal systolic BP (HR 1.49, 1.06-2.01). Among patients with prostate cancer treated with curative intent, those with a high diastolic BP (>90 mmHg) had a threefold increase in overall mortality risk (HR 3.01, 95% CI 1.40-6.46) compared with patients with a normal diastolic BP (<80 mmHg).

Conclusion: Our results support that systolic and diastolic BP are important factors when balancing disease management in patients with prostate cancer.

Keywords: hypertension; inflammation; mortality; prostate cancer; risk.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

[Hidden]

My BP went high shortly after ADT (might be because my testosterone was high). 25 mg of Losartan a day knocked it down. I picked that one because of the ARB research. My cardiologist agreed with the choice.